No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ELV Elevance Health
- 504.720
- -16.210-3.11%
Close Jul 18 16:00 ET
- 504.500
- -0.220-0.04%
Post 19:52 ET
117.04BMarket Cap17.67P/E (TTM)
513.740High494.167Low3.23MVolume507.380Open520.930Pre Close1.63BTurnover1.40%Turnover Ratio20.01P/E (Static)231.89MShares555.35552wk High2.77P/B116.75BFloat Cap427.36452wk Low6.22Dividend TTM231.31MShs Float555.355Historical High1.23%Div YieldTTM3.76%Amplitude16.546Historical Low504.223Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Elevance Health reported Q2 Profit And Revenue, Sticks To Annual Guidance
Elevance Health Inc. (NYSE:ELV) reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion. The decrease was driven by attrition in
Express News | Elevance Health Inc : TD Cowen Cuts Target Price to $589 From $624
TD Cowen Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $589
TD Cowen analyst Gary Taylor maintains $Elevance Health(ELV.US)$ with a buy rating, and adjusts the target price from $624 to $589.According to TipRanks data, the analyst has a success rate of 47.1%
BofA Downgrades Elevance Health On Medicaid Pressure And Lowered Peer Valuations
Wednesday, Elevance Health Inc. (NYSE:ELV) reported second-quarter revenues of $43.2 billion, down 0.4% year-over-year, marginally above the consensus of $43.05 billion. The decrease was driven by
Elevance Health's Medicaid Margin Outlook Has BofA Taking Sideline -- Market Talk
1359 ET - Managed care provider Elevance Health said Medicaid membership attrition was only partially offset by premium rate increases to reflect medical cost trends, when it reported operating
A Closer Look at Elevance Health's Options Market Dynamics
Financial giants have made a conspicuous bearish move on Elevance Health. Our analysis of options history for Elevance Health (NYSE:ELV) revealed 8 unusual trades.Delving into the details, we found 12
Comments
A flood of earnings will be coming over the next three weeks. This week will feature mostly financial companies.
Monday: Goldman Sachs ( $Goldman Sachs(GS.US$ ) and money manager Blackrock ( $Blackrock(BLK.US$ )
Tuesday: Health-insurer UnitedHealth Group ( $UnitedHealth(UNH.US$ ) , Bank of America ( $Bank of America(BAC.US$ ) , Morgan Stanley ( $Morgan Stanley(MS.US$ ) and Charles Schwab ( $Charles Schwab(SCHW.US$ ) .
Wednesday: Chip-equipment maker ASML ( $ASML Holding(ASML.US$ ) , pharm...
Monday: Goldman Sachs ( $Goldman Sachs(GS.US$ ) and money manager Blackrock ( $Blackrock(BLK.US$ )
Tuesday: Health-insurer UnitedHealth Group ( $UnitedHealth(UNH.US$ ) , Bank of America ( $Bank of America(BAC.US$ ) , Morgan Stanley ( $Morgan Stanley(MS.US$ ) and Charles Schwab ( $Charles Schwab(SCHW.US$ ) .
Wednesday: Chip-equipment maker ASML ( $ASML Holding(ASML.US$ ) , pharm...
2
RECAP
April rain better mean the stock market stops the pain by May: the market declined Tuesday, punctuated by the fall of fan favorite Tesla. The EV maker made less EV's than last year and dropped nearly 5%.
Stocks closed lower, the $S&P 500 Index(.SPX.US$ was recently down about 0.72%. $NASDAQ 100 Index(.NDX.US$ fell about 0.94%. $Dow Jones Industrial Average(.DJI.US$ fell 1%.
MACRO
Job openings recorded by JOLTS were just shy of expectations...
April rain better mean the stock market stops the pain by May: the market declined Tuesday, punctuated by the fall of fan favorite Tesla. The EV maker made less EV's than last year and dropped nearly 5%.
Stocks closed lower, the $S&P 500 Index(.SPX.US$ was recently down about 0.72%. $NASDAQ 100 Index(.NDX.US$ fell about 0.94%. $Dow Jones Industrial Average(.DJI.US$ fell 1%.
MACRO
Job openings recorded by JOLTS were just shy of expectations...
42
4
High insider ownership aligns management incentives with shareholders, but recent insider share sales, especially below current price, are concerning. Lack of insider purchases over the last year adds to the unease.
1
Market optimism grows for the stock after years of progress. Despite slowing share price gains, the business may continue to execute with prowess.
Elevance Health's performance is commendable, particularly its high rate of return and significant reinvestment into its business, which has led to impressive earnings growth. Analysts expect the company's earnings to gain momentum in the future.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg